In their latest interview, www.ceocfointerviews.com spent some time with Cardium Therapeutics (NYSE MKT: CXM) CEO and Chairman Christopher J. Reinhard.  The article title, “With their Regenerative Medicine Product Generx® for Coronary Artery Disease in Phase 3 Registration Study for International Markets, Cardium Therapeutics Inc. is Leading the Evolution of a Revolution” can be seen on the CEO/CFO Interviews website at:  http://www.ceocfointerviews.com/interviews/CXM-Cardium12.htm.

The Cardium chief (and founder) discusses the history of the company, company products/technologies (including Generx, Excellagen, ModPodium products), clinical trials, and what separates Cardium from other biotechnology companies.

---------------------------------

Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising.  Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated two thousand five hundred dollars by Cardium Therapeutics for its efforts in managing the dissemination of public corporate information on its website and to its database of subscribers and across select financial and social media websites.  Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.